Proximagen

About:

Proximagen is a neuroscience research company developing drugs for neurodegenerative disorders, including Parkinson’s and Alzheimers.

Website: http://www.proximagen.com

Top Investors: Lundbeck

Description:

Proximagen is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease.

Total Funding Amount:

$96.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2003-01-01

Contact Email:

info(AT)proximagen.com

Founders:

Peter Jenner

Number of Employees:

11-50

Last Funding Date:

2011-09-29

IPO Status:

Private

Industries: